Tiara Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 10-07-2024
- Paid Up Capital ₹ 0.90 M
as on 10-07-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 10-07-2024
- Satisfied Charges ₹ 4.05 M
as on 10-07-2024
- Revenue -26.23%
(FY 2021)
- Profit -48.17%
(FY 2021)
- Ebitda -96.98%
(FY 2021)
- Net Worth 8.69%
(FY 2021)
- Total Assets 0.81%
(FY 2021)
About Tiara Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹2.50 M. The company has closed loans amounting to ₹4.05 M, as per Ministry of Corporate Affairs (MCA) records.
Harbans Kaur, Paramjit Kaur, and Leena Gupta serve as directors at the Company.
- CIN/LLPIN
U51397PB2007PLC031140
- Company No.
031140
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 May 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Jalandhar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Tiara Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harbans Kaur  | Director | 07-Dec-2015 | Current |
| Paramjit Kaur | Director | 07-Dec-2015 | Current |
| Leena Gupta | Director | 16-May-2007 | Current |
Financial Performance of Tiara Life Sciences.
Tiara Life Sciences Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 26.23% decrease. The company also saw a substantial fall in profitability, with a 48.17% decrease in profit. The company's net worth moved up by a moderate rise of 8.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tiara Life Sciences?
In 2019, Tiara Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 11 Jan 2022 | ₹2.50 M | Open |
Icici Bank Limited Creation Date: 05 Oct 2015 | ₹2.50 M | Satisfied |
Icici Bank Limited Creation Date: 24 Oct 2011 | ₹0.65 M | Satisfied |
How Many Employees Work at Tiara Life Sciences?
Unlock and access historical data on people associated with Tiara Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tiara Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tiara Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
